| Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis S Kanters, M Vitoria, M Doherty, ME Socias, N Ford, JI Forrest, E Popoff, ... The lancet HIV 3 (11), e510-e520, 2016 | 218 | 2016 |
| Effect of frequency of clinic visits and medication pick‐up on antiretroviral treatment outcomes: a systematic literature review and meta‐analysis T Mutasa‐Apollo, N Ford, M Wiens, ME Socias, E Negussie, P Wu, ... Journal of the International AIDS Society 20, 21647, 2017 | 87 | 2017 |
| Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis S Kanters, ME Socias, NI Paton, M Vitoria, M Doherty, D Ayers, E Popoff, ... The lancet HIV 4 (10), e433-e441, 2017 | 83 | 2017 |
| Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma S Keeping, Y Xu, CI Chen, S Cope, A Mojebi, A Kuznik, G Konidaris, ... Future Oncology 17 (5), 611-627, 2021 | 44 | 2021 |
| Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature … R Sharma, L Wilkinson, H Vrazic, E Popoff, S Lopes, S Kanters, E Druyts Current Medical Research and Opinion 34 (9), 1595-1603, 2018 | 38 | 2018 |
| A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome Y Wang, K Johnston, E Popoff, KJ Myren, A Cheung, C Faria, I Tomazos Journal of Medical Economics 23 (12), 1503-1515, 2020 | 26 | 2020 |
| Aligning text mining and machine learning algorithms with best practices for study selection in systematic literature reviews E Popoff, M Besada, JP Jansen, S Cope, S Kanters Systematic reviews 9, 1-12, 2020 | 25 | 2020 |
| Unconditional cash transfers for clinical and economic outcomes among HIV-affected Ugandan households EJ Mills, A Adhvaryu, P Jakiela, J Birungi, S Okoboi, TNW Chimulwa, ... Aids 32 (14), 2023-2031, 2018 | 20 | 2018 |
| Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant–post hoc results from an open label safety study (BHV3000–201) K Johnston, L Harris, L Powell, E Popoff, V Coric, G L’Italien, ... The Journal of Headache and Pain 23 (1), 10, 2022 | 19 | 2022 |
| Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis K Johnston, E Popoff, A Deighton, P Dabirvaziri, L Harris, A Thiry, ... Expert Review of Pharmacoeconomics & Outcomes Research 22 (1), 155-166, 2022 | 18 | 2022 |
| Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature … S Kanters, L Wilkinson, H Vrazic, R Sharma, S Lopes, E Popoff, E Druyts BMJ open 9 (7), e023458, 2019 | 13 | 2019 |
| Mapping migraine-specific quality of life to health state utilities in patients receiving rimegepant KM Johnston, G L’Italien, E Popoff, L Powell, R Croop, A Thiry, L Harris, ... Advances in therapy 38, 5209-5220, 2021 | 12 | 2021 |
| Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma S Cope, K Toor, E Popoff, R Fonseca, O Landgren, MV Mateos, K Weisel, ... Value in Health 23 (4), 441-450, 2020 | 11 | 2020 |
| Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the … E Popoff, K Johnston, R Croop, A Thiry, L Harris, L Powell, V Coric, ... Headache: The Journal of Head and Face Pain 61 (6), 906-915, 2021 | 10 | 2021 |
| Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature … K O'Byrne, E Popoff, F Badin, A Lee, Y Yuan, G Lozano-Ortega, LJ Eccles, ... Lung Cancer 177, 11-20, 2023 | 9 | 2023 |
| Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study G L’Italien, E Popoff, K Johnston, D McGrath, CM Conway, L Powell, ... Cephalalgia Reports 5, 25158163221075596, 2022 | 9 | 2022 |
| Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome AR Levy, P Chen, K Johnston, Y Wang, E Popoff, I Tomazos Journal of Medical Economics 25 (1), 249-259, 2022 | 8 | 2022 |
| Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis S Goring, N Varol, N Waser, E Popoff, G Lozano-Ortega, A Lee, Y Yuan, ... Lung Cancer 170, 122-132, 2022 | 6 | 2022 |
| Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage AC Klimchak, SM Szabo, C Qian, E Popoff, S Iannaccone, KL Gooch Journal of managed care & specialty pharmacy 27 (10), 1426-1437, 2021 | 6 | 2021 |
| Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV. 2017; 4 (10): e433–41 S Kanters, ME Socias, NI Paton, M Vitoria, M Doherty, D Ayers, E Popoff, ... Epub 2017/08/09. pmid: 28784426 View Article PubMed/NCBI, 0 | 6 | |
